Why is it necessary to produce a BCG strain in Spain?

Unda, M.; Cozar-Olmo, J.M.; Alvarez-Osorio, J.L.

doi:10.1016/j.acuroe.2024.04.003

array:23 ["pii" => "S2173578624000301" "issn" => "21735786" "doi" => "10.1016/j.acuroe.2024.04.003" "estado" => "S300" "fechaPublicacion" => "2024-09-01" "aid" => "1630" "copyright" => "AEU" "copyrightAnyo" => "2024" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "edi" "cita" => "Actas Urol Esp. 2024;48:487-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0210480624000123" "issn" => "02104806" "doi" => "10.1016/j.acuro.2024.01.006" "estado" => "S300" "fechaPublicacion" => "2024-09-01" "aid" => "1630" "copyright" => "AEU" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "edi" "cita" => "Actas Urol Esp. 2024;48:487-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "Editorial" "titulo" => "¿Por qué es necesario tener una cepa de BCG fabricada en España?" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "487" "paginaFinal" => "489" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Why is it necessary to produce a BCG strain in Spain?" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1526 "Ancho" => 2925 "Tamanyo" => 303338 ] ] "descripcion" => array:1 [ "es" => "Estado del reclutamiento en octubre de 2023." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. Unda, J.M. Cozar-Olmo, J.L. Álvarez-Osorio" "autores" => array:3 [ 0 => array:2 [ "nombre" => "M." "apellidos" => "Unda" ] 1 => array:2 [ "nombre" => "J.M." "apellidos" => "Cozar-Olmo" ] 2 => array:2 [ "nombre" => "J.L." "apellidos" => "Álvarez-Osorio" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2173578624000301" "doi" => "10.1016/j.acuroe.2024.04.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173578624000301?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210480624000123?idApp=UINPBA00004N" "url" => "/02104806/0000004800000007/v1_202409020459/S0210480624000123/v1_202409020459/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2173578624000155" "issn" => "21735786" "doi" => "10.1016/j.acuroe.2024.02.008" "estado" => "S300" "fechaPublicacion" => "2024-09-01" "aid" => "1615" "copyright" => "AEU" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Actas Urol Esp. 2024;48:490-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "Review article" "titulo" => "Prevalence and management of urinary incontinece after pelvic organ prolapse surgery (sacrocolpopexy). A literature review" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "490" "paginaFinal" => "496" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Prevalencia y manejo de la incontinencia urinaria asociada a cirugía de prolapso órgano pélvico (colposacropexia). Revisión de la literatura" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "L. Polanco Pujol, J. Caño Velasco, E. Rodríguez Fernández, M.J. Cancho Gil, E. Lledó García, L. López-Fando Lavalle, C. Hernández Fernández" "autores" => array:7 [ 0 => array:2 [ "nombre" => "L." "apellidos" => "Polanco Pujol" ] 1 => array:2 [ "nombre" => "J." "apellidos" => "Caño Velasco" ] 2 => array:2 [ "nombre" => "E." "apellidos" => "Rodríguez Fernández" ] 3 => array:2 [ "nombre" => "M.J." "apellidos" => "Cancho Gil" ] 4 => array:2 [ "nombre" => "E." "apellidos" => "Lledó García" ] 5 => array:2 [ "nombre" => "L." "apellidos" => "López-Fando Lavalle" ] 6 => array:2 [ "nombre" => "C." "apellidos" => "Hernández Fernández" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0210480623001705" "doi" => "10.1016/j.acuro.2023.11.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210480623001705?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173578624000155?idApp=UINPBA00004N" "url" => "/21735786/0000004800000007/v1_202409020546/S2173578624000155/v1_202409020546/en/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "Editorial" "titulo" => "Why is it necessary to produce a BCG strain in Spain?" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "487" "paginaFinal" => "489" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "M. Unda, J.M. Cozar-Olmo, J.L. Alvarez-Osorio" "autores" => array:3 [ 0 => array:4 [ "nombre" => "M." "apellidos" => "Unda" "email" => array:1 [ 0 => "undaurzaiz@gmail.com" ] "referencia" => array:5 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:2 [ "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "J.M." "apellidos" => "Cozar-Olmo" "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "e" "identificador" => "aff0025" ] 2 => array:2 [ "etiqueta" => "f" "identificador" => "aff0030" ] ] ] 2 => array:3 [ "nombre" => "J.L." "apellidos" => "Alvarez-Osorio" "referencia" => array:4 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "g" "identificador" => "aff0035" ] 2 => array:2 [ "etiqueta" => "h" "identificador" => "aff0040" ] 3 => array:2 [ "etiqueta" => "i" "identificador" => "aff0045" ] ] ] ] "afiliaciones" => array:9 [ 0 => array:3 [ "entidad" => "Comité Científico del Ensayo Clínico ENCORE-01" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Laboratorio Mixto de Investigación Traslacional en Cáncer de Próstata, CICbioGUNE-Basurto, IIS Biobizkaia" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "CIBERONC" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Dirección Oficina de Relaciones con la Administración Sanitaria de la AEU" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Servicio de Urología, Hospital Universitario Virgen de las Nieves, Granada, Spain" "etiqueta" => "e" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Universidad de Granada, Granada, Spain" "etiqueta" => "f" "identificador" => "aff0030" ] 6 => array:3 [ "entidad" => "Servicio de Urología, Hospital Universitario Puerta del Mar, Cádiz, Spain" "etiqueta" => "g" "identificador" => "aff0035" ] 7 => array:3 [ "entidad" => "Presidencia de la Asociación Española de Urología (AEU)" "etiqueta" => "h" "identificador" => "aff0040" ] 8 => array:3 [ "entidad" => "Presidencia de la Fundación para la Investigación en Urología de la AEU" "etiqueta" => "i" "identificador" => "aff0045" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "¿Por qué es necesario tener una cepa de BCG fabricada en España?" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1523 "Ancho" => 2956 "Tamanyo" => 318847 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Recruitment status as of October 2023." ] ] ] "textoCompleto" => "Bladder cancer is one of the most prevalent tumors in our environment.<a class="elsevierStyleCrossRef" href="#bib0005">1</a> Approximately 22.000 cases are diagnosed annually in Spain, 70%–80% of which are non-muscle invasive<a class="elsevierStyleCrossRefs" href="#bib0010">2,3</a> and of these, one third are high-risk. The latter are defined as those having any of the following characteristics: Invading lamina propria (T1) and having highly undifferentiated cells (high grade, GIIb/GIII), with or without associated carcinoma in situ (CIS), isolated CIS without associated papillary, low grade Ta/T1 that also has all three risk factors: multiple, recurrent and >3 cm, high grade Ta that meets two of the above risk factors, low grade T1 with at least two of the risk factors.<a class="elsevierStyleCrossRef" href="#bib0020">4</a>In this scenario, and in the absence of more data from clinical trials being conducted with new molecules, BCG is the adjuvant treatment of choice after transurethral resection.<a class="elsevierStyleCrossRef" href="#bib0025">5</a>In April 2012, SANOFI-PASTEUR -the world's largest BCG producing center- ceased production of its Connaught strain of BCG, following an FDA inspection visit to its Toronto manufacturing facility. Considering that 80% of the world's production came from these facilities, this caused a worldwide shortage of unsuspected dimensions. Due to this fact, the biopharmaceutical companies that produced other strains tried to increase their production in order to cover the deficit generated. However, the results were uneven due to the difficulty involved in the manipulation of live organisms.The situation in Spain was similar to other countries without companies marketing their own BCG strain. The availability of BCG strains authorized by the Spanish Agency of Medicines and Health Products (AEMPS) and manufactured outside our borders was very variable as many countries had to be supplied and stock-outs had to be solved. As a result, the AEMPS decided to import strains that were unauthorized for marketing in Spain.This problem, which would initially have lasted only a few months, has persisted for more than 10 years. During this time, BCG availability in Spain has varied enormously. It has depended on the production of the different biopharmaceutical companies that produce it and on the worldwide demand, with the aggravating circumstance that only the unconsumed surplus in the country of origin could be acquired, as was the case in Japan. To alleviate the negative consequences of the lack of BCG on patients treated in our hospitals, the Spanish Association of Urology (AEU) guided the AEMPS to publish recommendations for the use of BCG, followed by all hospitals and Hospital Pharmacy Services in Spain, including alternatives available at that time.<a class="elsevierStyleCrossRefs" href="#bib0030">6,7</a> This absolute BCG shortage did not allow patients to receive adequate treatment according to the available scientific evidence. In face of this situation, the AEU contacted BIOFABRI Biopharmaceuticals, which had the necessary technology and facilities authorized by the AEMPS for the manufacture of product batches under Good Manufacturing Practices (GMP) conditions, to produce BCG in their facilities with some of the strains marketed in other countries, even though they were not authorized in Spain. The strain chosen was MOREAU RJ, developed in Brazil because of their experience in vaccine format and in intravesical treatment of NMIBT. This strain, similar to the Tokyo strain marketed mainly in Japan, is not capable of synthesizing PDIM (Phthiocerol Dimycocerosate), one of the most important lipids involved in its virulence, thus its safety could be guaranteed.<a class="elsevierStyleCrossRef" href="#bib0035">7</a> Several comparative studies have been carried out between the Moreau strain and other strains, but these have been mainly retrospective and with few patients. D'Andrea published their results comparing BCG-Moreau with BCG-TICE strains in intermediate or high-risk non-muscle-invasive bladder cancer. The authors found no differences in either recurrence-free or progression-free survival.<a class="elsevierStyleCrossRef" href="#bib0040">8</a> In this context, the Research Institute (IDI-URO) of the AEU is conducting a prospective clinical trial<a class="elsevierStyleCrossRef" href="#bib0045">9</a> ENCORE-01 (NCT03982797), in patients with high-risk NMIBC with or without associated carcinoma in situ or carcinoma in situ without associated papillary carcinoma. The trial uses the MOREAU-RJ strain developed by BIOFABRI (Porriño-Pontevedra) after undergoing a manufacturing quality and batch stability audit.The CUETO risk calculator<a class="elsevierStyleCrossRef" href="#bib0050">10</a> is used to stratify risk. Additionally, the protocol establishes all patients undergo a second transurethral resection to confirm the absence of disease when BCG instillations are started. Patients are instilled with 80 mg of IMUNO BCG Moreau-RJ. There are 6 instillations on induction phase (once per week) and a one-year maintenance phase with 3 instillations per week at 3, 6 and 12 months. The primary objective is to assess progression-free survival and the secondary objectives are to analyze disease-free survival, quality of life measured with the Functional Assessment of Cancer Therapy-Bladder questionnaire (FACT-BL version 4), adverse reactions and the drop-out rate due to toxicity. As an exploratory objective, the immune response is measured by cytokine analysis.<a class="elsevierStyleCrossRef" href="#bib0055">11</a> Fifteen centers committed to recruiting 306 patients, starting in 2019. Due to various reasons, including the pandemic, recruitment in most centers has not been as good as expected. <a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>.<elsevierMultimedia ident="fig0005"></elsevierMultimedia>An independent data monitoring committee has been set up, and its report will be sent to the AEMPS for a preliminary evaluation that may allow the Agency's approval of the investigated strain. This would constitute an important milestone in public hospitals, since we would no longer depend on other countries and their availability for supply of BCG.<a class="elsevierStyleCrossRef" href="#bib0060">12</a>FundingThe ENCORE-01 clinical trial has been funded by BIOFABRI SL.Conflicts of interestThe authors are members of the Scientific Committee of the ENCORE-01 Clinical Trial." "textoCompletoSecciones" => array:1 [ "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Funding" ] 1 => array:2 [ "identificador" => "sec0010" "titulo" => "Conflicts of interest" ] 2 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "multimedia" => array:1 [ 0 => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1523 "Ancho" => 2956 "Tamanyo" => 318847 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Recruitment status as of October 2023." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:12 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "F. Thomas" 1 => "A.P. Noon" 2 => "N. Rubin" 3 => "J.R. Goepel" 4 => "J.W. Catto" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eururo.2012.08.064" "Revista" => array:6 [ "tituloSerie" => "Eur Urol." "fecha" => "2013" "volumen" => "63" "paginaInicial" => "145" "paginaFinal" => "154" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22985746" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Red Española de Registros de Cáncer (REDECAN). <a target="_blank" href="http://hppts://stage.redecan.org">hppts://stage.redecan.org</a>. Last visit 19 Dec 2023." ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bladder cancer in Spain 2011: population based study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "B. Miñana" 1 => "J.M. Cózar" 2 => "J. Palou" 3 => "M. Unda Urzaiz" 4 => "R.A. Medina-Lopez" 5 => "J. Subirá Ríos" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.juro.2013.08.049.Epub2013" "Revista" => array:6 [ "tituloSerie" => "J Urol." "fecha" => "2014" "volumen" => "191" "paginaInicial" => "323" "paginaFinal" => "328" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23994371" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "European Association of Urology guidelines. [Accessed 19 Dec 2023] Available from: <a target="_blank" href="https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer">https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer</a>." ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of Bacillus Calmette-Guerin in the treatment of non–muscle-invasive bladder cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Gontero" 1 => "A. Bohle" 2 => "P.U. Malmstrom" 3 => "M.A. O’Donnell" 4 => "M. Oderda" 5 => "R. Sylvester" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eururo.2009.11.023" "Revista" => array:6 [ "tituloSerie" => "Eur Urol." "fecha" => "2010" "volumen" => "57" "paginaInicial" => "410" "paginaFinal" => "429" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19969411" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Actualización del desabastecimiento de BCG polvo para suspensión intravesical. Available from: <a target="_blank" href="https://www.aemps.gob.es/informa/notasinformativas/medicamentosusohumano-3/problemasSuministro/2014/ni-muh_33-2014-bcg-polvo/">https://www.aemps.gob.es/informa/notasinformativas/medicamentosusohumano-3/problemasSuministro/2014/ni-muh_33-2014-bcg-polvo/</a>." ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tratamiento del tumor vesical no músculo infiltrante frente al problema de disponibilidad de bacilo de Calmette-Guerin. Consenso de un panel de expertos españoles" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J.M. Fernández-Gómez" 1 => "J. Carballido-Rodríguez" 2 => "J.M. Cozar-Olmo" 3 => "J. Palou-Redorta" 4 => "E. Solsona-Narbón" 5 => "J.M. Unda-Urzaiz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.acuro.2013.04.002" "Revista" => array:6 [ "tituloSerie" => "Actas Urol Esp." "fecha" => "2013" "volumen" => "37" "paginaInicial" => "387" "paginaFinal" => "389" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23773824" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Genomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.M. Abdallah" 1 => "G.A. Hill-Cawthorne" 2 => "T.D. Otto" 3 => "F. Coll" 4 => "J.A. Guerra-Assuncao" 5 => "G. Gao" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/srep15443" "Revista" => array:5 [ "tituloSerie" => "Sci Rep." "fecha" => "2015" "volumen" => "5" "paginaInicial" => "15443" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26487098" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparative effectiveness of intravesical BCG-Tice and BCG-Moreau in patients with non-muscle-invasive bladder cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. D’Andrea" 1 => "F. Soria" 2 => "M. Abufaraj" 3 => "M. Pones" 4 => "P. Gontero" 5 => "A.T. Machado" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.clgc.2019.10.021" "Revista" => array:7 [ "tituloSerie" => "Clin Genitourin Cancer." "fecha" => "2020" "volumen" => "18" "paginaInicial" => "20" "paginaFinal" => "25" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31786120" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0140673620316007" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Clinicaltrials.gov/study/NCT03982797. Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis of Recurrence and Progression. [Accessed19 Dec 2023]." ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Fernandez-Gomez" 1 => "R. Madero" 2 => "E. Solsona" 3 => "M. Unda" 4 => "L. Martinez-Pineiro" 5 => "M. Gonzalez" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Urol." "fecha" => "2009" "volumen" => "182" "paginaInicial" => "2195" "paginaFinal" => "2203" ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Fernandez-Gomez JM, Unda-Urzaiz M, Alvarez-Ossorio JL, Cozar-Olmo JM. Br J Cancer Res. 2021;4:480-484. <a target="_blank" href="https://doi.org/10.31488/bjcr.165">https://doi.org/10.31488/bjcr.165</a>." ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21735786/0000004800000007/v1_202409020546/S2173578624000301/v1_202409020546/en/main.assets" "Apartado" => array:4 [ "identificador" => "6293" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Editorial" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21735786/0000004800000007/v1_202409020546/S2173578624000301/v1_202409020546/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173578624000301?idApp=UINPBA00004N"]

ISSN: 2173-5786

Actas Urológicas Españolas is an international journal dedicated to urological diseases and renal transplant. It has been the official publication of the Spanish Urology Association since 1974 and of the American Urology Confederation since 2008. Its articles cover all aspects related to urology. Actas Urológicas Españolas, governed by the peer review system (double blinded), is published online in Spanish and English. Consequently, manuscripts may be sent in Spanish or English and bidirectional free cost translation will be provided. It has high visibility and accessibility and is found in the most important data bases, Medline/Pubmed, Emabase, JCR, Ïndice Médico Español, Índice bibliográfico Español en Ciencias de la Salud (IBECS), Cuiden, Dialnet, Hinari, Scopus, Google Scholar.

See more Open Access Option

Indexed in:

Science Citation Index Expanded, Journal of Citation Reports, Index Medicus/MEDLINE, Scopus, EMBASE/Excerpta Medica, IBECS

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2023

1.2

Citescore

CiteScore measures average citations received per document published.

Citescore 2023

1.9

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2023

0.332

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2023

0.557

View more metrics

Journal Information

Previous article | Next article

Vol. 48. Issue 7.